TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY)
On 17 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
Published
Related content
- COVID-19 treatment: GlaxoSmithKline Australia Pty Ltd, sotrovimab (XEVUDY)On 20 August 2021 the TGA granted provisional approval to GlaxoSmithKline Australia Pty Ltd in relation to sotrovimab (XEVUDY).
- TGA receives application for an increased dose of GlaxoSmithKline’s COVID-19 treatment sotrovimab (XEVUDY) for the BA.2 Omicron sublineageThe TGA has received an application from GlaxoSmithKline (GSK) Australia Pty Ltd for a higher (1000 mg) dose of its COVID‑19 treatment, sotrovimab (XEVUDY)
- TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir)The TGA has granted provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir).